Akshat Katyayan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Akshat Katyayan has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
Gloria Diaz-Medina
Department of Pediatric Neurology and Developmental Neuroscience, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA
3 shared publications- Amanda G. Sandoval Karamian
Division of Pediatric Neurology, Department of Pediatrics University of Utah School of Medicine and Intermountain Primary Children’s Health Salt Lake City Utah USA
2 shared publications - Anuranjita Nayak
Division of Neurology and Developmental Neuroscience, Department of Pediatrics Texas Children's Hospital, Baylor College of Medicine Houston Texas USA
2 shared publications - Avantika Singh
Department of Neurology, Division of Child Neurology Medical College of Wisconsin Milwaukee Wisconsin USA
2 shared publications - Christina Briscoe Abath
Department of Neurology, Boston Children's Hospital, Boston, Massachusetts
2 shared publications Danielle S. Takacs
Division of Pediatric Neurology and Developmental Neuroscience, Texas Children’s Hospital Baylor College of Medicine Houston Texas USA
2 shared publications
Latest Publications
- Open Access
- 8 August 2026
- Published by Wiley in Epilepsia Open
- Vol. 11 (5) , 1478-1489
Management of Infantile Epileptic Spasms Syndrome: A survey of US pediatric hospitals
Objective: To evaluate the management practices of Infantile Epileptic Spasms Syndrome (IESS) across tertiary pediatric hospitals in the United States using a survey‐based approach. Methods: A 21‐question survey focused on management setting, work‐up, follow‐up and treatment was created and sent to 45 member institutions of the Pediatric Epilepsy Research Consortium (PERC). Results were analyzed by a working group of PERC focused on IESS. Results: Thirty‐three institutions completed the survey. Most institutions (91%) managed new‐onset IESS in‐patient, with 76% using overnight video EEG (vEEG) monitoring for diagnosis. Nearly all (> 90%) obtained an MRI brain and genetic testing at initial diagnosis. The most common modalities of genetic evaluation were an epilepsy panel (47%) and trio whole exome sequencing (44%). For assessment of response at the first follow‐up, 45% used extended vEEG (1–6 h), with 36% continuing to obtain overnight vEEG. The 2021 BASED score (Burden of Amplitude and Epileptiform Discharges) was the preferred method of assessing response (58%) compared to resolution of hypsarrhythmia (39%). High‐dose prednisolone was the first treatment for most institutions, irrespective of the etiology (apart from Tuberous Sclerosis Complex). Combined treatment (hormonal + vigabatrin) was less commonly used as first treatment (9%–12%, depending on etiology). Most institutions (63%) looked for failure of both hormonal therapy and vigabatrin (sequential or combined) before pursuing surgical treatment in patients with identifiable brain MRI lesions, but would also consider surgical treatment in patients with remission of electro‐clinical epileptic spasms but continued epileptiform EEGs. Significance: There are areas of consensus and variability in management of IESS in US institutions. Updated consensus guidelines addressing the comprehensive management of IESS are needed to help standardize and optimize care in these patients. Plain Language Summary: Infantile Epileptic Spasms Syndrome requires prompt diagnosis and initiation of appropriate treatment to improve developmental outcomes. In this survey of tertiary pediatric centers in the United States, we found areas of consensus (use of overnight video EEG at initial diagnosis, use of high‐dose prednisolone as initial treatment, preference for sequential as opposed to combination therapy, use of the 2021 BASED score for EEG evaluation, and the early consideration of epilepsy surgery) and variability (type of genetic testing for diagnosis, choice of second and third treatments, use of antiseizure medications for persistently epileptic EEG) in management of these patients.
- 8 August 2026
- Published by Wiley in Epilepsia Open
- Vol. 11 (5) , 1478-1489
Open AccessManagement of Infantile Epileptic Spasms Syndrome: A survey of US pediatric hospitals
Objective: To evaluate the management practices of Infantile Epileptic Spasms Syndrome (IESS) across tertiary pediatric hospitals in the United States using a survey‐based approach. Methods: A 21‐question survey focused on management setting, work‐up, follow‐up and treatment was created and sent to 45 member institutions of the Pediatric Epilepsy Research Consortium (PERC). Results were analyzed by a working group of PERC focused on IESS. Results: Thirty‐three institutions completed the survey. Most institutions (91%) managed new‐onset IESS in‐patient, with 76% using overnight video EEG (vEEG) monitoring for diagnosis. Nearly all (> 90%) obtained an MRI brain and genetic testing at initial diagnosis. The most common modalities of genetic evaluation were an epilepsy panel (47%) and trio whole exome sequencing (44%). For assessment of response at the first follow‐up, 45% used extended vEEG (1–6 h), with 36% continuing to obtain overnight vEEG. The 2021 BASED score (Burden of Amplitude and Epileptiform Discharges) was the preferred method of assessing response (58%) compared to resolution of hypsarrhythmia (39%). High‐dose prednisolone was the first treatment for most institutions, irrespective of the etiology (apart from Tuberous Sclerosis Complex). Combined treatment (hormonal + vigabatrin) was less commonly used as first treatment (9%–12%, depending on etiology). Most institutions (63%) looked for failure of both hormonal therapy and vigabatrin (sequential or combined) before pursuing surgical treatment in patients with identifiable brain MRI lesions, but would also consider surgical treatment in patients with remission of electro‐clinical epileptic spasms but continued epileptiform EEGs. Significance: There are areas of consensus and variability in management of IESS in US institutions. Updated consensus guidelines addressing the comprehensive management of IESS are needed to help standardize and optimize care in these patients. Plain Language Summary: Infantile Epileptic Spasms Syndrome requires prompt diagnosis and initiation of appropriate treatment to improve developmental outcomes. In this survey of tertiary pediatric centers in the United States, we found areas of consensus (use of overnight video EEG at initial diagnosis, use of high‐dose prednisolone as initial treatment, preference for sequential as opposed to combination therapy, use of the 2021 BASED score for EEG evaluation, and the early consideration of epilepsy surgery) and variability (type of genetic testing for diagnosis, choice of second and third treatments, use of antiseizure medications for persistently epileptic EEG) in management of these patients.
- Open Access
Clinical outcomes following stereotactic MRI ‐guided laser ablation in children with tuberous sclerosis complex and intractable epilepsy
Objective: In children with tuberous sclerosis complex (TSC) and drug‐resistant epilepsy (DRE), magnetic resonance imaging–guided stereotactic laser ablation (SLA) therapy offers less‐invasive treatment compared to craniotomy and resection. Our study seeks to further expand on the long‐term outcomes in patients with TSC‐related DRE who have undergone SLA. Methods: Patients with TSC and DRE treated with SLA, between July 1, 2016 and January 1, 2022, at our institution were identified retrospectively. Reduction in number of anti‐seizure medications (ASMs), developmental improvement as reported by the patients' families, seizure frequency measured in surgically targeted seizure type and total seizures per day, and Engel classification were evaluated at 6 months, 1 year, 2 years, and thereafter at the most recent follow‐up visit if available. Results: Forty patients (ages 11 months to 23 years, median age 3.6 years) with TSC underwent SLA. Total follow‐up was on average 2.9 years post‐surgery. Significant (>50%) reduction in total seizure frequency occurred in 80% of patients ( n = 32), with 63% of patients reporting a >90% reduction in seizure frequency ( n = 25) at last follow‐up. Fifty‐eight percent had complete freedom from their surgically targeted seizure type ( n = 23). At last follow up, perceived developmental gains occurred in 63% ( n = 25), reduction in ASM occurred in 40% ( n = 16), and Engel class was III or less in 93% of patients ( n = 37). Significance: SLA was safe and effective for most patients, even the very young. A majority of patients achieved improvement in seizure frequency, including the surgically targeted seizure type, but less than half were able to reduce medications. Reported developmental improvement was related to Engel outcomes. Future studies utilizing neuropsychological testing in the full cohort will be required to offer objective insights into post‐operative development profiles.
Open AccessClinical outcomes following stereotactic MRI ‐guided laser ablation in children with tuberous sclerosis complex and intractable epilepsy
Objective: In children with tuberous sclerosis complex (TSC) and drug‐resistant epilepsy (DRE), magnetic resonance imaging–guided stereotactic laser ablation (SLA) therapy offers less‐invasive treatment compared to craniotomy and resection. Our study seeks to further expand on the long‐term outcomes in patients with TSC‐related DRE who have undergone SLA. Methods: Patients with TSC and DRE treated with SLA, between July 1, 2016 and January 1, 2022, at our institution were identified retrospectively. Reduction in number of anti‐seizure medications (ASMs), developmental improvement as reported by the patients' families, seizure frequency measured in surgically targeted seizure type and total seizures per day, and Engel classification were evaluated at 6 months, 1 year, 2 years, and thereafter at the most recent follow‐up visit if available. Results: Forty patients (ages 11 months to 23 years, median age 3.6 years) with TSC underwent SLA. Total follow‐up was on average 2.9 years post‐surgery. Significant (>50%) reduction in total seizure frequency occurred in 80% of patients ( n = 32), with 63% of patients reporting a >90% reduction in seizure frequency ( n = 25) at last follow‐up. Fifty‐eight percent had complete freedom from their surgically targeted seizure type ( n = 23). At last follow up, perceived developmental gains occurred in 63% ( n = 25), reduction in ASM occurred in 40% ( n = 16), and Engel class was III or less in 93% of patients ( n = 37). Significance: SLA was safe and effective for most patients, even the very young. A majority of patients achieved improvement in seizure frequency, including the surgically targeted seizure type, but less than half were able to reduce medications. Reported developmental improvement was related to Engel outcomes. Future studies utilizing neuropsychological testing in the full cohort will be required to offer objective insights into post‐operative development profiles.
- 10 October 2025
- Published by Elsevier in Pediatric Neurology
- Vol. 174, 46-53
Treatment Practices for Infantile Epileptic Spasms Syndrome: Consensus and Variation in Major Pediatric Epilepsy Centers
- 10 October 2025
- Published by Elsevier in Pediatric Neurology
- Vol. 174, 46-53
Treatment Practices for Infantile Epileptic Spasms Syndrome: Consensus and Variation in Major Pediatric Epilepsy Centers
Characteristics of overnight video‐EEG monitoring in infantile epileptic spasms syndrome at 2‐week follow‐up
Objective: To determine the optimal duration of electroencephalography (EEG) recording to detect epileptic spasms (ES) based on inpatient overnight video‐EEG monitoring in patients with infantile epileptic spasms syndrome (IESS) at the 2‐week follow‐up.Methods: Patients with IESS and overnight EEG monitoring between January 2020 and June 2022 were retrospectively reviewed. Time‐to‐ES, time‐to‐sleep and time‐to‐epileptic encephalopathy (EE) per the Burden of Amplitudes and Epileptiform Discharges (BASED 2021) score. BASED 2021 score were reported. ES and sleep detection sensitivity were calculated with respect to monitoring time. Etiology, treatment, and EEG features were assessed for strength of association with continued ES. Time‐to‐event analysis was performed with the first ES as the event of interest.Results: Of 90 patients, 39 (43%) continued to have ES; 78.6% with EE continued to have ES, whereas only 27.4% without EE had ES (odds ratio [OR] 12.05). Structural etiologies were also associated with continued ES (OR 5.24). ES detection was 35.9%, 76.9%, and 84.6% at 1, 4, and 6 h, respectively, with corresponding negative likelihood ratios (NLRs) of .64, .23, and .15. ES detection reached >90% and >95% at 14 and 19 h, respectively. Sleep detection was 52.2%, 84.4%, and 95.6% at 1, 4, and 6 h, respectively, and captured in all patients by 11 h. EE was observed by 6 h for all associated patients.Significance: Typical routine EEG durations (95% of patients with ES. Although EE was strongly associated with continued ES, 27.4% of patients without EE demonstrated ES. This study will help guide adequate duration of EEG monitoring at the 2‐week follow‐up for patients with IESS.
Characteristics of overnight video‐EEG monitoring in infantile epileptic spasms syndrome at 2‐week follow‐up
Objective: To determine the optimal duration of electroencephalography (EEG) recording to detect epileptic spasms (ES) based on inpatient overnight video‐EEG monitoring in patients with infantile epileptic spasms syndrome (IESS) at the 2‐week follow‐up.Methods: Patients with IESS and overnight EEG monitoring between January 2020 and June 2022 were retrospectively reviewed. Time‐to‐ES, time‐to‐sleep and time‐to‐epileptic encephalopathy (EE) per the Burden of Amplitudes and Epileptiform Discharges (BASED 2021) score. BASED 2021 score were reported. ES and sleep detection sensitivity were calculated with respect to monitoring time. Etiology, treatment, and EEG features were assessed for strength of association with continued ES. Time‐to‐event analysis was performed with the first ES as the event of interest.Results: Of 90 patients, 39 (43%) continued to have ES; 78.6% with EE continued to have ES, whereas only 27.4% without EE had ES (odds ratio [OR] 12.05). Structural etiologies were also associated with continued ES (OR 5.24). ES detection was 35.9%, 76.9%, and 84.6% at 1, 4, and 6 h, respectively, with corresponding negative likelihood ratios (NLRs) of .64, .23, and .15. ES detection reached >90% and >95% at 14 and 19 h, respectively. Sleep detection was 52.2%, 84.4%, and 95.6% at 1, 4, and 6 h, respectively, and captured in all patients by 11 h. EE was observed by 6 h for all associated patients.Significance: Typical routine EEG durations (95% of patients with ES. Although EE was strongly associated with continued ES, 27.4% of patients without EE demonstrated ES. This study will help guide adequate duration of EEG monitoring at the 2‐week follow‐up for patients with IESS.
- Open Access
- 16 September 2024
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 39 (11-12) , 395-402
Acute Changes in Liver Function Tests During Initiation of Ketogenic Diet
Background: Ketogenic diet is an effective therapy for patients with medically refractory epilepsy. It is generally well tolerated, with the most common side effects being gastrointestinal. Hepatic toxicity has been described as an uncommon side effect of ketogenic diet, usually with long-term use. However, there are limited data to implicate ketogenic diet in acute liver toxicity. Methods and results: We analyzed all patients who underwent elective inpatient ketogenic diet initiation at our institution from June 2019 to June 2022. Of the 25 patients reviewed, we found 6 patients who showed acute, asymptomatic changes in liver function tests during initiation, in both hepatocellular and cholestatic patterns. Two patients stopped the ketogenic diet acutely and 3 patients continued ketogenic diet with changes in medications and/or addition of choline—all patients had improvement and normalization of liver function tests in the short term. One patient had acute normalization of chronically elevated liver function tests on ketogenic diet initiation. Conclusion: Ketogenic diet can cause acute changes in liver function tests during initiation of ketogenic diet, with both hepatocellular and cholestatic patterns, with and without the concurrent use of hepatotoxic medications. In most patients, ketogenic diet can be continued successfully by making changes to medications or addition of choline.
- 16 September 2024
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 39 (11-12) , 395-402
Open AccessAcute Changes in Liver Function Tests During Initiation of Ketogenic Diet
Background: Ketogenic diet is an effective therapy for patients with medically refractory epilepsy. It is generally well tolerated, with the most common side effects being gastrointestinal. Hepatic toxicity has been described as an uncommon side effect of ketogenic diet, usually with long-term use. However, there are limited data to implicate ketogenic diet in acute liver toxicity. Methods and results: We analyzed all patients who underwent elective inpatient ketogenic diet initiation at our institution from June 2019 to June 2022. Of the 25 patients reviewed, we found 6 patients who showed acute, asymptomatic changes in liver function tests during initiation, in both hepatocellular and cholestatic patterns. Two patients stopped the ketogenic diet acutely and 3 patients continued ketogenic diet with changes in medications and/or addition of choline—all patients had improvement and normalization of liver function tests in the short term. One patient had acute normalization of chronically elevated liver function tests on ketogenic diet initiation. Conclusion: Ketogenic diet can cause acute changes in liver function tests during initiation of ketogenic diet, with both hepatocellular and cholestatic patterns, with and without the concurrent use of hepatotoxic medications. In most patients, ketogenic diet can be continued successfully by making changes to medications or addition of choline.
- 25 August 2023
- Published by Elsevier in Pediatric Neurology
- Vol. 149, 63-68
Propofol for Anesthesia in Pediatric Patients With Epilepsy on the Ketogenic Diet: A Single-Center Experience
- 25 August 2023
- Published by Elsevier in Pediatric Neurology
- Vol. 149, 63-68
Propofol for Anesthesia in Pediatric Patients With Epilepsy on the Ketogenic Diet: A Single-Center Experience
- 19 May 2023
- Published by Elsevier in Pediatric Neurology
- Vol. 145, 119-123
Inaccuracies in Parental Reporting of Treated Epileptic Spasms: Both Under- and Over-Reporting
- 19 May 2023
- Published by Elsevier in Pediatric Neurology
- Vol. 145, 119-123
Inaccuracies in Parental Reporting of Treated Epileptic Spasms: Both Under- and Over-Reporting